# ABOS Adult Reconstruction
Recertification Examination Blueprint

## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hip</strong></td>
<td>24-56%</td>
</tr>
<tr>
<td><strong>Knee</strong></td>
<td>24-56%</td>
</tr>
<tr>
<td><em>Perioperative management</em></td>
<td>7-13%</td>
</tr>
<tr>
<td><em>General Principles</em></td>
<td>5-15%</td>
</tr>
<tr>
<td>Topic</td>
<td>Percentage</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Anatomy and surgical approach</td>
<td>1-3%</td>
</tr>
<tr>
<td>Biomechanics</td>
<td>1-3%</td>
</tr>
<tr>
<td>Fractures, femoral neck (including stress)</td>
<td>1-3%</td>
</tr>
<tr>
<td>Fractures (intertrochanteric, subtrochanteric)</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td>Periprosthetic fracture (intraoperative and postoperative)</td>
<td>1-3%</td>
</tr>
<tr>
<td>Nonoperative management (pain management, injections, assistive devices, physical therapy, weight loss)</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td>Developmental hip dysplasia</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>4-6%</td>
</tr>
<tr>
<td>Inflammatory arthritis</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td>Post-traumatic arthritis</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td>Instability</td>
<td>2-4%</td>
</tr>
<tr>
<td>Femoral acetabular impingement</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td>Osteonecrosis</td>
<td>1-3%</td>
</tr>
<tr>
<td>Complications (neurovascular, heterotopic ossification, leg length discrepancy, intraoperative, device failure, medical)</td>
<td>4-6%</td>
</tr>
<tr>
<td>Infection</td>
<td>2-4%</td>
</tr>
<tr>
<td>Painful arthroplasty (iliopsoas impingement, tendinopathy, referred pain)</td>
<td>1-3%</td>
</tr>
<tr>
<td>Aseptic loosening</td>
<td>1-3%</td>
</tr>
<tr>
<td>Osteolysis</td>
<td>1-3%</td>
</tr>
<tr>
<td>Adverse local tissue reaction</td>
<td>1-3%</td>
</tr>
<tr>
<td>Condition</td>
<td>Percentage</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Anatomy and surgical approach</td>
<td>1-3%</td>
</tr>
<tr>
<td>Biomechanics</td>
<td>1-3%</td>
</tr>
<tr>
<td><strong>Nonoperative management</strong> (pain management, injections, assistive devices, physical therapy, weight loss)</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td><strong>Osteoarthritis</strong> (partial knee arthroplasty, osteotomy, total knee arthroplasty)</td>
<td>4-6%</td>
</tr>
<tr>
<td>Inflammatory arthritis</td>
<td>1-3%</td>
</tr>
<tr>
<td>Post-traumatic arthritis</td>
<td>1-3%</td>
</tr>
<tr>
<td>Instability</td>
<td>1-3%</td>
</tr>
<tr>
<td>Osteonecrosis</td>
<td>0.5-1.5%</td>
</tr>
<tr>
<td><strong>Complications</strong> (neurovascular, heterotopic ossification, compartment syndrome, intraoperative, device failure, medical, recurrent hemarthrosis)</td>
<td>4-6%</td>
</tr>
<tr>
<td>Infection</td>
<td>2-4%</td>
</tr>
<tr>
<td><strong>Painful arthroplasty</strong> (tendinopathy, referred pain, neuroma)</td>
<td>1-3%</td>
</tr>
<tr>
<td>Aseptic loosening</td>
<td>2-4%</td>
</tr>
<tr>
<td>Osteolysis</td>
<td>1-3%</td>
</tr>
<tr>
<td><strong>Periprosthetic fracture</strong> (intraoperative and postoperative)</td>
<td>1-3%</td>
</tr>
<tr>
<td>Extensor mechanism complications</td>
<td>2-4%</td>
</tr>
<tr>
<td>Stiffness</td>
<td>1-3%</td>
</tr>
</tbody>
</table>
### Perioperative management

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preoperative</strong></td>
<td>(infection and medical optimization, including nutrition, smoking cessation, glucose management/diabetes, weight loss, MRSA screening, multimodal pain management, prehabilitation, inflammatory arthritis evaluation and management)</td>
<td>4-6%</td>
</tr>
<tr>
<td><strong>Intraoperative</strong></td>
<td>(anesthesia/blocks, blood loss prevention, infection prevention, multimodal pain management, wound management)</td>
<td>1-3%</td>
</tr>
<tr>
<td><strong>Postoperative</strong></td>
<td>(multimodal pain management, rehabilitation, wound management, blood management, discharge disposition)</td>
<td>2-4%</td>
</tr>
<tr>
<td><strong>General Principles</strong></td>
<td>5-15%</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Biostatistics/epidemiology</td>
<td>0.5-1.5%</td>
<td></td>
</tr>
<tr>
<td>Legal/ethical</td>
<td>0.5-1.5%</td>
<td></td>
</tr>
<tr>
<td>Basic science (biology, biomaterials)</td>
<td>1-3%</td>
<td></td>
</tr>
<tr>
<td><strong>Lumbar spine</strong> (spondylosis, disc disease, and stenosis, diagnosis only)</td>
<td>0.5-1.5%</td>
<td></td>
</tr>
<tr>
<td><strong>Neoplasms</strong> (metastatic, primary bone neoplasm)</td>
<td>0.5-1.5%</td>
<td></td>
</tr>
<tr>
<td><strong>Thromboembolic disease and bleeding disorders</strong> (risk assessment, prophylaxis, and treatment)</td>
<td>1-3%</td>
<td></td>
</tr>
<tr>
<td><strong>Neurologic</strong> (polio, Parkinsons, dementia, Charcot)</td>
<td>0.5-1.5%</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolic bone disease</strong> (osteoporosis, fragility fractures)</td>
<td>0.5-1.5%</td>
<td></td>
</tr>
</tbody>
</table>